Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SCYNEXIS Inc SCYX

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.


NDAQ:SCYX - Post by User

Comment by dmacdon Aug 17, 2021 2:35pm
76 Views
Post# 33717940

RE:RE:RE:Drug just got approved! :)

RE:RE:RE:Drug just got approved! :)Wow. These biopharma stocks are truly in show me stage for valuation. Great opportunity for those with high conviction (like me) to load up way more than you thought you could. Sales will start slow since it takes some time to gain momentum but imagine if sales take off faster than the market expects ... at any rate I am sitting back on a load of core shares and will buy a trading position if it goes much lower. Good chance of 10x in 12 months if Q3 / Q4 sales shows promising signs.

Might be one more bad quarter though ... hard to say how much pent up demand there is for this and how long it will take to get the marketing team to start showing results. Lots of cash to whether a slow ramp ... so that is comforting. I am done with the dilutive financings and hopefully management finally want their options to be worth something. 

Wild card is Merck to buy out for $2 billiion ... if the IV drip Phase 1 shows good safety results then watch out for that. Surely management would not sell for less since they can secure a nice position with a white knight if Merck cheaps out on the offer. 

Look for Merck to potentially cause a short sale though to test management resolve. All speculative but for sure they are watching carefully and hoping for a misstep on sales. 

Cheers
<< Previous
Bullboard Posts
Next >>